← Back to headlines
Cheap Semaglutide Copies from India Challenge Novo Nordisk and Eli Lilly
A report indicates that the availability of inexpensive semaglutide copies in India is posing a significant challenge to pharmaceutical giants Novo Nordisk and Eli Lilly, potentially eroding their market lead.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
